Translating Basic Research into Safe and Effective Cell-based Treatments for Respiratory Diseases
Ikonomou, Laertis ; Wagner, Darcy E LU
; Turner, Leigh
and Weiss, Daniel J
(2019)
In Annals of the American Thoracic Society
16(6).
p.657-668
- Abstract
Respiratory diseases, such as chronic obstructive pulmonary disease and pulmonary fibrosis, result in severely impaired quality of life and impose significant burdens on healthcare systems worldwide. Current disease management involves pharmacologic interventions, oxygen administration, reduction of infections, and lung transplantation in advanced disease stages. An increasing understanding of mechanisms of respiratory epithelial and pulmonary vascular endothelial maintenance and repair and the underlying stem/progenitor cell populations, including but not limited to airway basal cells and type II alveolar epithelial cells, has opened the possibility of cell replacement-based regenerative approaches for treatment of lung diseases.... (More)
Respiratory diseases, such as chronic obstructive pulmonary disease and pulmonary fibrosis, result in severely impaired quality of life and impose significant burdens on healthcare systems worldwide. Current disease management involves pharmacologic interventions, oxygen administration, reduction of infections, and lung transplantation in advanced disease stages. An increasing understanding of mechanisms of respiratory epithelial and pulmonary vascular endothelial maintenance and repair and the underlying stem/progenitor cell populations, including but not limited to airway basal cells and type II alveolar epithelial cells, has opened the possibility of cell replacement-based regenerative approaches for treatment of lung diseases. Further potential for personalized therapies, including in vitro drug screening, has been underscored by the recent derivation of various lung epithelial, endothelial, and immune cell types from human induced pluripotent stem cells. In parallel, immunomodulatory treatments using allogeneic or autologous mesenchymal stromal cells have shown a good safety profile in clinical investigations for acute inflammatory conditions such as acute respiratory distress syndrome and septic shock. As yet, no cell-based therapy has been shown to be both safe and effective for any lung disease. Despite the investigational status of cell-based interventions for lung diseases, businesses that market unproven, unlicensed and potentially harmful cell-based interventions for respiratory diseases have proliferated in the U.S. and worldwide. The current status of various cell-based regenerative approaches for lung disease as well as the effect of the regulatory environment on clinical translation of such approaches are presented and critically discussed in this review.
(Less)
- author
- Ikonomou, Laertis
; Wagner, Darcy E
LU
; Turner, Leigh
and Weiss, Daniel J
- organization
- publishing date
- 2019-03-27
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of the American Thoracic Society
- volume
- 16
- issue
- 6
- pages
- 657 - 668
- publisher
- American Thoracic Society
- external identifiers
-
- scopus:85066435433
- pmid:30917290
- ISSN
- 2325-6621
- DOI
- 10.1513/AnnalsATS.201812-890CME
- language
- English
- LU publication?
- yes
- id
- 49affb9b-87ee-4fde-8639-15d4b95ad0e9
- date added to LUP
- 2019-03-31 19:00:20
- date last changed
- 2024-07-09 08:57:13
@article{49affb9b-87ee-4fde-8639-15d4b95ad0e9,
abstract = {{<p>Respiratory diseases, such as chronic obstructive pulmonary disease and pulmonary fibrosis, result in severely impaired quality of life and impose significant burdens on healthcare systems worldwide. Current disease management involves pharmacologic interventions, oxygen administration, reduction of infections, and lung transplantation in advanced disease stages. An increasing understanding of mechanisms of respiratory epithelial and pulmonary vascular endothelial maintenance and repair and the underlying stem/progenitor cell populations, including but not limited to airway basal cells and type II alveolar epithelial cells, has opened the possibility of cell replacement-based regenerative approaches for treatment of lung diseases. Further potential for personalized therapies, including in vitro drug screening, has been underscored by the recent derivation of various lung epithelial, endothelial, and immune cell types from human induced pluripotent stem cells. In parallel, immunomodulatory treatments using allogeneic or autologous mesenchymal stromal cells have shown a good safety profile in clinical investigations for acute inflammatory conditions such as acute respiratory distress syndrome and septic shock. As yet, no cell-based therapy has been shown to be both safe and effective for any lung disease. Despite the investigational status of cell-based interventions for lung diseases, businesses that market unproven, unlicensed and potentially harmful cell-based interventions for respiratory diseases have proliferated in the U.S. and worldwide. The current status of various cell-based regenerative approaches for lung disease as well as the effect of the regulatory environment on clinical translation of such approaches are presented and critically discussed in this review.</p>}},
author = {{Ikonomou, Laertis and Wagner, Darcy E and Turner, Leigh and Weiss, Daniel J}},
issn = {{2325-6621}},
language = {{eng}},
month = {{03}},
number = {{6}},
pages = {{657--668}},
publisher = {{American Thoracic Society}},
series = {{Annals of the American Thoracic Society}},
title = {{Translating Basic Research into Safe and Effective Cell-based Treatments for Respiratory Diseases}},
url = {{http://dx.doi.org/10.1513/AnnalsATS.201812-890CME}},
doi = {{10.1513/AnnalsATS.201812-890CME}},
volume = {{16}},
year = {{2019}},
}